Navigation Links
Potential new treatment for gastrointestinal cancers discovered
Date:1/17/2013

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

The complex of proteins, known as mTorc1 (mammalian target of rapamycin complex 1), has previously been implicated in the development of some other cancers but this is the first time it has been shown to promote the growth of colon and gastric cancers that are associated with inflammation.

Dr Stefan Thiem and Associate Professor Matthias Ernst from the Walter and Eliza Hall Institute's Cell Signalling and Cell Death division made the discovery with colleagues while at the Melbourne-Parkville Branch of the Ludwig Institute for Cancer Research. Associate Professor Ernst is a Ludwig Institute Member. Their findings are published online today in the Journal of Clinical Investigation.

Cancers of the digestive system are a significant cause of death in Australia. Colon (or bowel) cancer causes more than 4000 deaths annually more than any other cancer except lung cancer while more than 1000 Australians die from gastric (or stomach) cancer each year.

Ernst said many types of colon and gastric cancer were associated with chronic inflammation. "We have previously shown that the immune system's inflammatory response can promote the growth of tumours," he said. "In the digestive system, persistent inflammatory conditions have been linked with tumour growth: patients who have stomach ulcers or gastritis (inflammation of the stomach lining) are more susceptible to gastric cancer, while inflammation of the colon, called colitis, is associated with an increased risk of developing colon cancer."

The research team found that inflammation-associated gastric and colon cancers showed activation of mTorc1, an aggregate of proteins that signals inside cells to promote growth. Many cancer types depend on mTorc1 activity to grow, and there is considerable interest in the use of mTorc1 inhibitors to treat cancer.

The growth of inflammation-associated colon and gastric cancers could be treated with mTorc1 inhibitors, Ernst said. "We were excited to discover that the growth of these cancers in laboratory models could be prevented by treatment with mTorc1 inhibitors that are already in clinical trials for other types of cancer," he said. "In the future, we hope that this finding might lead to better treatment options for colon and gastric cancers that are associated with inflammation. Since there are also other types of cancer that are associated with inflammation, we suspect that these could also be susceptible to treatment with mTorc1 inhibitors."


'/>"/>

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute

Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research


Source:Eurekalert  

Related medicine news :

1. Da Vinci Surgery Robot Lawsuit Website Launched by Bernstein Leibhard LLP to Inform Public about Potential Da Vinci Surgery Complications
2. Impending Mandate on Event Data Recorders Raises Concern amongst Auto Manufactures - Kiley Law Group Weighs in on Potential to Save Lives
3. High-throughput sequencing shows potentially hundreds of gene mutations related to autism
4. Honda Issues Recall of 800K Vehicles, Philadelphia Attorneys at Console & Hollawell Warn Consumers of Their Potential Risks
5. Robotic-assisted radical bladder surgery potentially benefits bladder cancer patients
6. UAlberta medical researchers discover new potential chemotherapy
7. New screening approach identified potential drug combos for difficult-to-treat melanomas
8. Frog-in-bucket-of-milk folklore leads to potential new antibiotics
9. ‘A Subtle Addiction – Attacking the Y Generation’ - New Book by Peter & Lynn McIntosh Begs the Question "Is an Ipad, Kindle or Smart Phone a Safe Gift or a Potential Radiation Cancer Risk this Holiday Season?"
10. Potential gene therapy approach to sickle cell disease highlighted at American Society of Hematology
11. Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential new treatment for gastrointestinal cancers discovered
(Date:7/21/2017)... ... 21, 2017 , ... Sharon Kleyne is proud of the ... research center at Bio-Logic Aqua Research® Water Life Science®, has been released in ... sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to eliminating ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing ... by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the ... 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: